JP2019089796A5 - - Google Patents

Download PDF

Info

Publication number
JP2019089796A5
JP2019089796A5 JP2019009896A JP2019009896A JP2019089796A5 JP 2019089796 A5 JP2019089796 A5 JP 2019089796A5 JP 2019009896 A JP2019009896 A JP 2019009896A JP 2019009896 A JP2019009896 A JP 2019009896A JP 2019089796 A5 JP2019089796 A5 JP 2019089796A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
receptor antagonist
kit
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019009896A
Other languages
English (en)
Japanese (ja)
Other versions
JP6790140B2 (ja
JP2019089796A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019089796A publication Critical patent/JP2019089796A/ja
Publication of JP2019089796A5 publication Critical patent/JP2019089796A5/ja
Application granted granted Critical
Publication of JP6790140B2 publication Critical patent/JP6790140B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019009896A 2013-03-14 2019-01-24 下痢を治療するための製品及び方法 Active JP6790140B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361782608P 2013-03-14 2013-03-14
US61/782,608 2013-03-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018054088A Division JP6473254B2 (ja) 2013-03-14 2018-03-22 下痢を治療するための製品及び方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020184294A Division JP2021046400A (ja) 2013-03-14 2020-11-04 下痢を治療するための製品及び方法

Publications (3)

Publication Number Publication Date
JP2019089796A JP2019089796A (ja) 2019-06-13
JP2019089796A5 true JP2019089796A5 (enExample) 2019-10-24
JP6790140B2 JP6790140B2 (ja) 2020-11-25

Family

ID=50680150

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016502404A Active JP6313417B2 (ja) 2013-03-14 2014-03-14 下痢を治療するための製品及び方法
JP2018054088A Active JP6473254B2 (ja) 2013-03-14 2018-03-22 下痢を治療するための製品及び方法
JP2019009896A Active JP6790140B2 (ja) 2013-03-14 2019-01-24 下痢を治療するための製品及び方法
JP2020184294A Pending JP2021046400A (ja) 2013-03-14 2020-11-04 下痢を治療するための製品及び方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2016502404A Active JP6313417B2 (ja) 2013-03-14 2014-03-14 下痢を治療するための製品及び方法
JP2018054088A Active JP6473254B2 (ja) 2013-03-14 2018-03-22 下痢を治療するための製品及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020184294A Pending JP2021046400A (ja) 2013-03-14 2020-11-04 下痢を治療するための製品及び方法

Country Status (20)

Country Link
US (4) US9717726B2 (enExample)
EP (3) EP3269364B1 (enExample)
JP (4) JP6313417B2 (enExample)
KR (4) KR20180088514A (enExample)
CN (2) CN108939076A (enExample)
AU (3) AU2014239878B2 (enExample)
BR (2) BR122017004716A2 (enExample)
CA (1) CA2906005C (enExample)
DK (1) DK2968205T3 (enExample)
ES (2) ES2655505T3 (enExample)
HK (1) HK1247557B (enExample)
HU (1) HUE035201T2 (enExample)
IL (3) IL273377B2 (enExample)
MX (2) MX366329B (enExample)
MY (1) MY175326A (enExample)
PL (1) PL2968205T3 (enExample)
PT (1) PT2968205T (enExample)
RU (1) RU2015143475A (enExample)
WO (1) WO2014152420A2 (enExample)
ZA (1) ZA201708539B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717726B2 (en) 2013-03-14 2017-08-01 Maregade Rx, LLC Product and method for treating diarrhea
US20150132410A1 (en) * 2013-11-14 2015-05-14 Michael M. Jacobs Compositions and methods for the prevention and treatment of alcohol-induced hangover syndrome
US20180185356A1 (en) * 2016-12-23 2018-07-05 Maregade Rx, LLC Low dose product and method for treating diarrhea
IT201900012645A1 (it) * 2019-07-23 2021-01-23 Eros Zanotti Una composizione farmaceutica per l'uso nel trattamento delle chinetosi
CN112616320B (zh) * 2019-08-05 2024-04-05 株式会社日立高新技术 等离子处理装置
CN115515435A (zh) * 2020-02-11 2022-12-23 沃尔夫森医疗中心 有效治疗溃疡性结肠炎的方法
CN117280446A (zh) 2021-08-23 2023-12-22 株式会社日立高新技术 等离子处理装置以及等离子处理方法
WO2023049205A1 (en) 2021-09-22 2023-03-30 Hista Rx Llc Compositions and methods for treating and preventing interstitial cystitis

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204118A (en) 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
US5096894A (en) * 1990-04-03 1992-03-17 Bristol-Myers Squibb Company Rice dextrin oral rehydration solution
AU7255094A (en) 1993-07-06 1995-02-06 Mcneil-Ppc, Inc. H2 antagonist-antihistamine combinations
US6264984B1 (en) * 1999-12-06 2001-07-24 Bristol-Myers Squibb Company Effervescent histamine H2 antagonist composition
US6656492B2 (en) * 2000-06-30 2003-12-02 Yamanouchi Pharmaceutical Co., Ltd. Quick disintegrating tablet in buccal cavity and manufacturing method thereof
CA2430292A1 (en) 2000-11-30 2002-06-06 The Bio Balance Corp. Preparation of compositions comprising bacterial strains and volatile plant extracts and therapeutic and industrial applications thereof
WO2003044023A1 (en) * 2001-11-23 2003-05-30 Janssen Pharmaceutica N.V. The use of anti-histaminics for acute reduction of elevated intracranial pressure
SE528789C2 (sv) 2004-09-10 2007-02-13 Sandvik Intellectual Property PVD-belagt skär av hårdmetall samt sätt att tillverka detta
US20070077300A1 (en) * 2005-09-30 2007-04-05 Wynn David W Oral compositions containing a salivation inducing agent
US20090312358A1 (en) 2006-03-22 2009-12-17 Trustees Of Boston University Method for management of diarrhea
US8207188B2 (en) 2006-04-07 2012-06-26 Michalis Nicolaou Treatment of diseases modulated by a H4 receptor agonist
US8207292B2 (en) 2007-02-12 2012-06-26 Michalis Nicolaou Treatment of COPD, gastro-esophageal reflux disease (GERD), food allergies and other gastrointestinal conditions and disorders ameliorated by proper histamine management using a combination of histidine decarboxylase inhibitors, LRA drugs, anti-H1 and/or anti-H2 drugs
US20070254050A1 (en) * 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
US20090042972A1 (en) * 2006-05-19 2009-02-12 Somaxon Pharmaceuticals, Inc. Methods of using low-dose doxepin for the improvement of sleep
CA2721133C (en) * 2007-04-13 2018-11-06 Somaxon Pharmaceuticals, Inc. Low-dose doxepin formulations and methods of making and using the same
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
EP3415627A1 (en) 2012-11-13 2018-12-19 Codiak BioSciences, Inc. Delivery of therapeutic agent
US9717726B2 (en) 2013-03-14 2017-08-01 Maregade Rx, LLC Product and method for treating diarrhea
US20180185356A1 (en) 2016-12-23 2018-07-05 Maregade Rx, LLC Low dose product and method for treating diarrhea

Similar Documents

Publication Publication Date Title
HRP20160189T1 (hr) Liječenje crohnove bolesti lakvinimodom
JP2009525343A5 (enExample)
HRP20121072T1 (hr) Postupci za davanje tetrahidrobiopterina, povezani pripravci i postupci mjerenja
CN110801452B (zh) 一种含有阿利沙坦酯水解产物或其水解产物盐的药物组合物及其用途
JP2010522242A5 (enExample)
EP2248519A3 (en) Non-mucoadhesive film dosage forms
HRP20240564T1 (hr) Novi farmaceutski sastav
JP2006104221A5 (enExample)
JP2005512995A5 (enExample)
JP2019503365A5 (enExample)
RU2015143475A (ru) Продукт и способ лечения диареи
JP2015515475A5 (enExample)
FI3782612T3 (fi) Sytidiinianalogien oraalisia formulaatioita ja menetelmiä niiden käyttämiseksi
HRP20201316T1 (hr) Novi modulatori receptora sfingozin-fosfata
JP2015511609A5 (enExample)
IL278188B1 (en) Sublingual formulation of riluzole
JP2015514739A5 (enExample)
JP2010522137A5 (enExample)
JP2012502915A5 (enExample)
NZ591408A (en) Paracetamol and Calcium carbonate composition
JP2023531930A5 (enExample)
JP2011516544A5 (enExample)
UA100883C2 (ru) Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона
RU2005105302A (ru) Композиция бицифадина
JP2012041314A5 (enExample)